Evidence map›Paper›PMID 34662447›Full record

ArticleThe Prostate2022

Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.

Sangyub Kim, Li Li, Jinhui Zhang, Cheng Jiang, Junxuan Lü

Open access · bronzeAbstract read
In one paragraph

Article in The Prostate, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Sangyub KimDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Li LiDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Jinhui ZhangDepartment of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Cheng JiangDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Junxuan LüDepartment of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Texas Tech University Health Sciences Center · USPennsylvania State University · USTexas Tech University · US

Funding

PREVENTION OF PROSTATE CARCINOGENESIS BY NEXT-GENERATION SELENIUMR01CA172169 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI LU, JUNXUAN · 2013 to 2018
$1.6M
Translational development studies of a novel combination therapy for castration-resistant prostate cancerR21CA218774 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI DENG, YIBIN, LU, JUNXUAN · 2018 to 2019
$377k
NCI NIH HHS R01 CA172169NCI NIH HHS R21 CA218774
6 · The paper itself

Abstract

backgroundMetabolic reprograming is now a recognized hallmark of cancer. The prostate-specific phosphatase and tensin homolog deleted on chromosome 10 (Pten) gene-conditional knockout (KO) mouse carcinogenesis model is highly desirable for studying prostate cancer biology and prevention due to its close resemblance of primary molecular defects and histopathological features of human prostate cancer. We have recently published macromolecular profiling of this model by proteomics and transcriptomics, denoting a preeminence of inflammation and myeloid suppressive immune cell features. Here, we performed metabolomic analyses of Pten-KO prostate versus wild type (WT) counterpart for discernable changes in the aqueous metabolites and contrasted to those in the TRAMP neuroendocrine carcinoma (NECa).

methodsThree matched pairs of tissue-specific conditional Pten-KO mouse prostate and WT prostate of litter/cage-mates at 20-22 weeks of age and three pairs of TRAMP NECa versus WT (28-31 weeks) were profiled for their global aqueous metabolite changes, using hydrophilic interaction liquid chromatography-tandem mass spectrometry.

resultsThe Pten-KO prostate increased purine nucleotide pools, cystathionine, and both reduced and oxidized glutathione (GSH, GSSG), and gluconate/glucuronate species in addition to cholesteryl sulfate and polyamine precursor ornithine. On the contrary, Pten-KO prostate contained diminished pools of glycolytic intermediates and phosphorylcholine derivatives, select amino acids, and their metabolites. Bioinformatic integration revealed a significant shunting of glucose away from glycolysis-citrate cycle and glycerol-lipid genesis to pentose phosphate cycle for NADPH/GSH/GSSG redox and pentose moieties for purine and pyrimidine nucleotides, and glycosylation/glucuronidation. Implicit arginine catabolism to ornithine was consistent with immunosuppression in Pten-KO model. While also increased in cystathionine-GSH/GSSG, purine, and pyrimidine nucleotide pools and glucuronidation at the expense of glycolysis-citrate cycle, the TRAMP NECa increased abundance of many amino acids, methyl donor S-adenosyl-methionine, and intermediates for phospholipids without increasing cholesteryl sulfate or ornithine.

conclusionsThe aqueous metabolomic patterns in Pten-KO prostate and TRAMP NECa shared similarities in the greater pools of cystathionine, GSH/GSSG redox pair, and nucleotides and shunting away from glycolysis-citrate cycle in both models. Remarkable metabolic distinctions between them included metabolisms of many amino acids (protein synthesis; arginine-ornithine/immune suppression) and cholesteryl sulfate and methylation donor for epigenetic regulations.

Indexed as

Carcinoma, NeuroendocrineProstateProstatic NeoplasmsAnimalsBiomarkersChromatography, LiquidDisease Models, AnimalMaleMetabolomicsMiceMice, KnockoutPTEN PhosphohydrolaseReceptors, Tumor Necrosis Factor, Member 25Tandem Mass SpectrometryBiomarkersPTEN PhosphohydrolasePten protein, mouseReceptors, Tumor Necrosis Factor, Member 25Tnfrsf25 protein, mouseadenocarcinomametabolic biomarkersneuroendocrine carcinomaprostate cancer

Identifiers

PMID34662447
PMCPMC9298286
OpenAlexW3206684239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.